Combining electronic healthcare databases in Europe to allow for large‐scale drug safety monitoring: the EU‐ADR Project
Top Cited Papers
- 8 November 2010
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 20 (1) , 1-11
- https://doi.org/10.1002/pds.2053
Abstract
Purpose In this proof‐of‐concept paper we describe the framework, process, and preliminary results of combining data from European electronic healthcare record (EHR) databases for large‐scale monitoring of drug safety. Methods Aggregated demographic, clinical, and prescription data from eight databases in four countries (Denmark, Italy, Netherlands, the UK) were pooled using a distributed network approach by generation of common input data followed by local aggregation through custom‐built software, Jerboa©. Comparison of incidence rates of upper gastrointestinal bleeding (UGIB) and nonsteroidal anti‐inflammatory drug (NSAID) utilization patterns were used to evaluate data harmonization and quality across databases. The known association of NSAIDs and UGIB was employed to demonstrate sensitivity of the system by comparing incidence rate ratios (IRRs) of UGIB during NSAID use to UGIB during all other person‐time. Results The study population for this analysis comprised 19 647 445 individuals corresponding to 59 929 690 person‐years of follow‐up. 39 967 incident cases of UGIB were identified during the study period. Crude incidence rates varied between 38.8 and 109.5/100 000 person‐years, depending on country and type of database, while age‐standardized rates ranged from 25.1 to 65.4/100 000 person‐years. NSAID use patterns were similar for databases within the same country but heterogeneous among different countries. A statistically significant age‐ and gender‐adjusted association between use of any NSAID and increased risk for UGIB was confirmed in all databases, IRR from 2.0 (95%CI:1.7–2.2) to 4.3 (95%CI: 4.1–4.5). Conclusions Combining data from EHR databases of different countries to identify drug‐adverse event associations is feasible and can set the stage for changing and enlarging the scale for drug safety monitoring. Copyright © 2010 John Wiley & Sons, Ltd.Keywords
This publication has 47 references indexed in Scilit:
- A distributed research network model for post‐marketing safety studies: the Meningococcal Vaccine StudyPharmacoepidemiology and Drug Safety, 2008
- Primer: administrative health databases in observational studies of drug effects—advantages and disadvantagesNature Clinical Practice Rheumatology, 2007
- Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjectsJournal of Psychopharmacology, 2007
- A Self-scaling, Distributed Information Architecture for Public Health, Research, and Clinical CareJournal of the American Medical Informatics Association, 2007
- Introduction of newer selective cyclo-oxygenase-2 inhibitors and rates of hospitalization with bleeding and perforated peptic ulcerAlimentary Pharmacology & Therapeutics, 2007
- Cancer risk among users of neuroleptic medication: a population-based cohort studyBritish Journal of Cancer, 2006
- Spironolactone and risk of upper gastrointestinal events: population based case-control studyBMJ, 2006
- Evaluating Drug Effects in the Post-Vioxx WorldCirculation, 2006
- Exploring the effect of transient exposure on the risk of acute events by means of time‐window designs: an application to fluoroquinolone antibacterials and arrhythmiaPharmacoepidemiology and Drug Safety, 2005
- Merck withdraws arthritis drug worldwideBMJ, 2004